Literature DB >> 7545468

Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro.

A Mackensen1, B Herbst, G Köhler, G Wolff-Vorbeck, F M Rosenthal, H Veelken, P Kulmburg, H E Schaefer, R Mertelsmann, A Lindemann.   

Abstract

It is well established by in vivo and in vitro studies that dendritic cells (DCs) originate from hematopoietic progenitor cells. However, the presumed intermediate of Birbeck granule (BG)+ Langerhans cells (LCs) has not been detected in cultures derived from bone marrow or peripheral blood progenitor cells (PBPCs), thus contrasting with the data obtained with cord blood. We show here that large numbers of BG+ LCs can be generated from human CD34+ PBPCs in vitro, when granulocyte-macrophage colony-stimulating factor and interleukin-4, potent promotors of LC/DC differentiation, are combined with a cocktail of early acting hematopoietic growth factors. LCs were found to emerge from CD33+CD11b+CD14- progenitor cells that they share with the monocytic lineage. During culture, these cells exhibited a sequence of dramatic morphologic changes, starting with a major increase in granularity followed by an increase in size herein exceeding that of all peripheral blood cells. At the same time, CD1a and major histocompatibility complex class II expression were upregulated and virtually all CD1a++ cells were BG+ by electron microscopy. With prolonged culture, CD1a was downregulated on a major population of cells, paralleled by a loss of BG and an increase of CD4, CD25, and CD80 expression that may correspond to the maturation of epidermal LC in vitro. However, these cells were consistently CD5- and did not exhibit changes in the CD45-isoform expression during culture. The availability of large numbers of these highly purified BG+ LCs and mature DCs allows for specific analysis of these subpopulations and provides a source of potent antigen-presenting cells from individual patients for vaccination protocols against infectious or tumor-associated antigens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545468

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Efficient ex vivo generation of human dendritic cells from mobilized CD34+ peripheral blood progenitors.

Authors:  K Ohishi; N Katayama; H Mitani; H Araki; M Masuya; H Suzuki; N Hoshino; H Miyashita; K Nishii; S Kageyama; N Minami; H Shiku
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

Review 2.  Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.

Authors:  R Hájek; A W Butch
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

3.  HIV-1 infection of placental cord blood monocyte-derived dendritic cells.

Authors:  R M Folcik; J D Merrill; Y Li; C J Guo; S D Douglas; S E Starr; W Z Ho
Journal:  J Hematother Stem Cell Res       Date:  2001-10

4.  RARα supports the development of Langerhans cells and langerin-expressing conventional dendritic cells.

Authors:  Seika Hashimoto-Hill; Leon Friesen; Sungtae Park; Suji Im; Mark H Kaplan; Chang H Kim
Journal:  Nat Commun       Date:  2018-09-25       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.